EQL Pharma AB Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of SEK 2.32 billion. The enterprise value is 2.46 billion.

Market Cap	2.32B
Enterprise Value	2.46B

Important Dates

The next estimated earnings date is Wednesday, February 5, 2025.

Earnings Date	Feb 5, 2025
Ex-Dividend Date	n/a

Share Statistics

EQL Pharma AB has 29.06 million shares outstanding. The number of shares has decreased by -1.96% in one year.

Current Share Class	n/a
Shares Outstanding	29.06M
Shares Change (YoY)	-1.96%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.15%
Owned by Institutions (%)	8.43%
Float	11.62M

Valuation Ratios

The trailing PE ratio is 74.57 and the forward PE ratio is 33.96.

PE Ratio	74.57
Forward PE	33.96
PS Ratio	7.33
PB Ratio	11.72
P/TBV Ratio	250.49
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 44.31, with an EV/FCF ratio of -125.90.

EV / Earnings	78.77
EV / Sales	7.76
EV / EBITDA	44.31
EV / EBIT	51.50
EV / FCF	-125.90

Financial Position

The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.75.

Current Ratio	1.24
Quick Ratio	0.47
Debt / Equity	0.75
Debt / EBITDA	2.67
Debt / FCF	-7.60
Interest Coverage	5.73

Financial Efficiency

Return on equity (ROE) is 17.11% and return on invested capital (ROIC) is 10.30%.

Return on Equity (ROE)	17.11%
Return on Assets (ROA)	8.51%
Return on Capital (ROIC)	10.30%
Revenue Per Employee	15.82M
Profits Per Employee	1.56M
Employee Count	21
Asset Turnover	0.90
Inventory Turnover	1.59

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +136.10% in the last 52 weeks. The beta is 0.63, so EQL Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.63
52-Week Price Change	+136.10%
50-Day Moving Average	70.34
200-Day Moving Average	55.27
Relative Strength Index (RSI)	59.28
Average Volume (20 Days)	36,075

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of SEK 316.38 million and earned 31.18 million in profits. Earnings per share was 1.07.

Revenue	316.38M
Gross Profit	136.66M
Operating Income	47.69M
Pretax Income	39.30M
Net Income	31.18M
EBITDA	53.95M
EBIT	47.69M
Earnings Per Share (EPS)	1.07

Full Income Statement

Balance Sheet

The company has 11.83 million in cash and 148.22 million in debt, giving a net cash position of -136.39 million or -4.69 per share.

Cash & Cash Equivalents	11.83M
Total Debt	148.22M
Net Cash	-136.39M
Net Cash Per Share	-4.69
Equity (Book Value)	197.89M
Book Value Per Share	6.81
Working Capital	45.79M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -18.78 million and capital expenditures -727,000, giving a free cash flow of -19.51 million.

Operating Cash Flow	-18.78M
Capital Expenditures	-727,000
Free Cash Flow	-19.51M
FCF Per Share	-0.67

Full Cash Flow Statement

Margins

Gross margin is 43.19%, with operating and profit margins of 15.07% and 9.85%.

Gross Margin	43.19%
Operating Margin	15.07%
Pretax Margin	12.42%
Profit Margin	9.85%
EBITDA Margin	17.05%
EBIT Margin	15.07%
FCF Margin	n/a

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.96%
Shareholder Yield	1.96%
Earnings Yield	1.34%
FCF Yield	-0.84%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a